Table 2.

Studies on hypofractionated SBRT for different lesions’ sites.

	Study year	No. of patients	No. of lung lesions	Primary site	Dose	LC	Toxicity
Wersall et al.	2005	58	117/162	Renal-cell carcinoma (RCC)	30–40 Gy/3 fr/1 week	Median follow-up of 37 months LC 90%	G3 (pneumonitis) in 5 pts
Svedman et al.	2006	30	63/82	RCC	40 Gy/4 fr/every second day	Median follow-up of 52 months LC 98%	G1-2 90% G5 (lung) 3.3% (one pt)
Milano et al.	2008/2012	121	103/293	All (mostly breast and colorectal)	50 Gy/10 fr/over two weeks	2–4 year LC 77%, 73%	G3 (lung) in one pt
Kang et al.	2010	59	18/78	Colorectal carcinoma	39–51 Gy/3 fr	3-year LC 66%	G1-2 (lung) in 6 pt (46%)
Inoue et al.	2010	41	22/60	All (mostly lung)	35 Gy/4 fr	3-year LC 80%	Intercostal neuralgia in one pt
Salama et al.	2011	61	41/113	All (mostly lung)	24–48 Gy/3 fr (3 radiation doses separated by >48 and <192 h)	2-year LC 66.7%	G3 (fatigue) in 2 pt G3 (lung) in one pt G3 (neurologic) in one pt
Stinauer et al.	2011	30	39/53	Melanoma and RCC	40–50 Gy/5 fr 42–60 Gy/3 fr (fractions could be given on consecutive days or separated with intervening days)	18-months actuarial LC 88%	G3 (hypoxia) in one pt G3 (pneumonitis) in one pt